Having gestational diabetes, or even elevated glucose levels during pregnancy, may be associated with increased risk of metabolic syndrome and cardiovascular disease (CVD) later, according to three recent studies.
In the past month, a new meta-analysis compared metformin to other diabetes drugs, and the FDA expanded metformin's indications in patients with reduced kidney function.
Experts addressed minimizing cardiovascular risk, managing diabetes in the ICU, altering protocols, and monitoring glucose levels, while studies looked at insulin infusion and other interventions for patients with COVID-19.
Recent research quantified the association between visit-to-visit variability in HbA1c levels and risk of cardiovascular disease and death.
Recent analyses of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial looked at the effects of fenofibrate on gout and cardiovascular events in patients with type 2 diabetes.
Experts gave advice on which diabetes drugs should be stopped in patients with COVID-19, and studies highlighted associations between the two diseases.
Recent studies found higher HbA1c levels in younger patients with diabetes compared to older ones, as well as differences in medication therapy by age.
Two recent studies considered whether initiation of second-line therapies in patients already taking metformin for type 2 diabetes occurs too soon or too late.
Recent studies analyzed depression in diabetes, including associated causes of death, the potential benefits of peer support and a plant-based diet, and strategies for screening and treatment.
One recent study reported on the development and validation of an artificial intelligence algorithm for detecting diabetic retinopathy, while another tested such technology in primary care.